Abstract:In our continuing efforts to develop novel c-Met inhibitors as potential anticancer candidates, a series of new N-sulfonylamidine derivatives were designed, synthesized via Cu-catalyzed multicomponent reaction (MCR) as the key step, and evaluated for their in vitro biological activities against c-Met kinase and four cancer cell lines (A549, HT-29, MKN-45 and MDA-MB-231). Most of the target compounds showed moderate to significant potency at both the enzyme-based and cell-based assay and possessed selectivity for A549 and HT-29 cancer cell lines. The preliminary SAR studies demonstrated that compound 26af (c-Met IC50 = 2.89 nM) was the most promising compound compared with the positive foretinib, which exhibited the remarkable antiproliferative activities, with IC50 values ranging from 0.28 to 0.72 μM. Mechanistic studies of 26af showed the anticancer activity was closely related to the blocking phosphorylation of c-Met, leading to cell cycle arresting at G2/M phase and apoptosis of A549 cells by a concentration-dependent manner. The promising compound 26af was further identified as a relatively selective inhibitor of c-Met kinase, which also possessed an acceptable safety profile and favorable pharmacokinetic properties in BALB/c mouse. The favorable drug-likeness of 26af suggested that N-sulfonylamidines may be used as a promising scaffold for antitumor drug development. Additionally, the docking study and molecular dynamics simulations of 26af revealed a common mode of interaction with the binding site of c-Met. These positive results indicated that compound 26af is a potential anti-cancer candidate for clinical trials, and deserves further development as a selective c-Met inhibitor.

Discovery Of Novel C-Met Inhibitors Bearing A 3-Carboxyl Piperidin-2-One Scaffold

Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors

Discovery of novel type II c-Met inhibitors based on BMS-777607.

Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors

Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors

Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors

Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity

Design, Synthesis and Biological Evaluation of C-Met Kinase Inhibitors Bearing 2-Oxo-1,2-dihydroquinoline Scaffold

Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (C-Met) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(quinolin-6-ylmethyl)-1h-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1h-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment Of

Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors

Pyridazinone Derivatives Displaying Highly Potent and Selective Inhibitory Activities Against C-Met Tyrosine Kinase.

Structure-guided design and development of novel N-phenylpyrimidin-2-amine derivatives as potential c-Met inhibitors

Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors

Discovery of Novel Inhibitors for C-Met by Virtual Screening and Pharmacophore Analysis

Design, synthesis, biological evaluation, and docking studies of novel triazolo[4,3- b]pyridazine derivatives as dual c-Met/Pim-1 potential inhibitors with antitumor activity

Design, synthesis and biological evaluation of thienopyridine derivatives as c-Met kinase inhibitors

Enhancing the Cellular Anti-Proliferation Activity of Pyridazinones As C-Met Inhibitors Using Docking Analysis.

Design and Synthesis of Novel Substituted Naphthyridines As Potential C-Met Kinase Inhibitors Based on Mk-2461

Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction

Design, Synthesis and Biological Evaluation of Novel α‐Acyloxycarboxamide‐Based Derivatives as c‐Met Inhibitors

Discovery and Optimization of the First ATP Competitive Type-III c-MET Inhibitor